



Women and Children's Health Network RSV PREVENTION TOOLKIT 2026–2027 SEASON

UPDATED OCTOBER 2026



Women & Children's
Health Network
CENTRAL REGION



DISCLAIMER

This Respiratory Syncytial Virus (RSV) Prevention Toolkit is intended for use by healthcare professionals and administrative staff involved in the prevention and management of RSV in perinatal and pediatric care settings. The information provided herein is based on current guidelines from the Provincial Council for Maternal and Child Health (PCMCH), National Advisory Committee on Immunization (NACI) and Ontario Health Guidelines.

This toolkit is not a substitute for clinical judgment or institutional policies. Users are responsible for ensuring that all practices comply with local regulations, organizational protocols, and the most current clinical evidence. Consent forms and educational materials should be reviewed and adapted to meet the legal and linguistic needs of your patient population.

The authors and contributors of this toolkit assume no liability for the use or misuse of the information contained within.

2026-2027 Season Updates:

Season start date: October 1, 2026

Nirsevimab (Beyfortus®):

Currently funded for RSV prophylaxis in infants who are residents of Ontario and meet any of the following criteria (unchanged from last year):

- Infants born April 1 or after and who are less than 8 months of age at the time of immunization.
- Children less than 24 months of age who remain vulnerable to severe RSV disease, and following a discussion with their pediatrician or pediatric specialist

RSVpreF (Abrysvo®):

Can be used for pregnant women between **28–36 weeks** gestation who will deliver during the RSV season

- There is currently no recommendation for repeat vaccine dosing for subsequent pregnancies.
- To provide RSV protection to infants born in subsequent pregnancies, administration of a monoclonal antibody (nirsevimab) to the infant after birth is recommended.

While RSVpreF (Abrysvo®) is authorized by Health Canada for use in pregnant persons between 32 and 36 weeks gestation, NACI recommends that RSVpreF may be administered between 28 and 36 weeks gestation. This recommendation is supported by available safety and efficacy data, supports broader access and opportunities for immunization, and aligns with recommendations by the World Health Organization. Administration before 32 weeks gestation is considered off-label and is subject to the sole clinical judgment of the health care provider.





Parents and caregivers are encouraged to discuss these two options with their health care provider. After reviewing the information, the choice of which option to use rests with the parent(s) or caregiver.

- In April of 2026, the National Advisory Committee on Immunization (NACI) removed its preferential recommendation for monoclonal antibodies.
- NACI recognizes both nirsevimab (Beyfortus®) and RSVpreF (Abrysvo®) as effective strategies for preventing severe RSV in Infants.
- Emerging evidence suggests RSVpreF (Abrysvo®) and nirsevimab (Beyfortus®) **provide similar protection** against severe RSV in infants.

Ordering and Access Information:

Beyfortus® (nirsevimab) and Abrysvo® (RSVpreF) are **not available through pharmacies** this RSV season. Health care providers can order these products through their usual vaccine source: their local Public Health Unit or the Ontario Government Pharmaceutical and Medical Supply Service (OGPMSS).



Billing code G849: Providers are strongly encouraged to use this code to support accurate capture of RSV immunization administration data.

If your practice does not offer these products, direct patients to a designated clinic to confirm eligibility and book an appointment. A list of RSV catch-up and immunization clinics across Central Region has been compiled and can be found on [page 9](#).

2025-2026 Season Update:

- 71.8% of Infants received RSV immunizations
- Ministry Target was 90% and remains the same for 2026-27 Season
- This includes both nirsevimab (Beyfortus®) or RSVpreF (Abrysvo®) administration
- For more information regarding statistics please reach out to your BORN coordinators





2026-2027 Eligibility Criteria:

There are no changes to the eligibility Criteria for Beyfortus. It is publicly funded for eligible individuals who are Ontario residents and meet the following criteria:

Nirsevimab (Beyfortus®)

Infants and children who meet any one of the following criteria:

- Infants born April 1 or after and less than 8 months of age at the time of immunization.
- Children less than 24 months of age who remain vulnerable to severe RSV disease, following a discussion with their pediatric specialist including children with:
 - Chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), defined by need for ongoing respiratory support and supplemental oxygen therapy at 36 weeks postmenstrual age (gestational age at birth plus chronological age) or discharged home, if earlier.
 - Note: Children who were less 12 months of age and approved for coverage in the previous RSV season for chronic lung disease and bronchopulmonary dysplasia remain eligible, irrespective of their clinical status in the second RSV season.
 - Hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD) defined as infants requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension.
 - Severe immunodeficiency
 - Down syndrome/Trisomy 21
 - Cystic fibrosis with recurrent pulmonary exacerbations requiring hospitalization, deteriorating pulmonary function and/or severe growth delay
 - Neuromuscular disease impairing clearing of respiratory secretions
 - Severe congenital airway anomalies impairing the clearing of respiratory secretions

RSVpreF Vaccine (Abrysvo®)

Through Ontario's RSV prevention program, RSVpreF (Abrysvo®) is publicly funded for pregnant individuals who are between 28 and 36 weeks of gestation and are expected to deliver during the RSV season. Eligible individuals can receive the vaccine after discussing it with their health care provider.

Administration of both RSVpreF (Abrysvo®) during pregnancy and nirsevimab (Beyfortus®) to the infant is NOT routinely recommended, except in the following circumstances:

- Infants born less than 14 days after administration of RSVpreF (Abrysvo®)
OR
- Infants at increased risk of severe RSV disease, including:
 - All premature infants (i.e., less than 37 weeks gestation)
- Infants who meet any of the above high-risk criteria





RSV Catch-Up Clinics for Infants

For infants:

- Born outside the RSV season,
- Whose parent did not receive Abrysvo® during pregnancy,
- Who were born this RSV season and have not yet received Beyfortus®
- Who are high risk and in their second RSV season (see Eligibility Criteria)

Direct families to a designated RSV catch-up clinic to confirm eligibility and book an appointment

[*Click here for a list of catch-up/Immunization clinics within Central Region*](#)

BORN

Better Outcomes Registry Network (BORN) integrated new RSV-related data elements into the BORN Information System (BIS) starting October 31, 2024. These include:

- Administration and date of prenatal vaccine RSVpreF (Abrysvo®)
- Administration and date of infant monoclonal antibody nirsevimab (Beyfortus®)
- Reason for non-administration
- High-risk criteria

BORN also developed RSV-specific reports to help hospitals and midwifery practice groups monitor uptake and outcomes locally and provincially.

BORN Ontario RSV Protection Webinar: Reaching Provincial Targets for Better Infant Outcomes Together
Webinar: [Respiratory Syncytial Virus | BORN Ontario](#)





PCMCH RSV Fact Sheets

PCMCH is pleased to share fact sheets to support parents, caregivers, expectant parents, and healthcare providers with information about RSV and available prevention options. These resources align with Ontario's RSV prevention program for the current 2026/2027 RSV season.

For Parents and Expectant Parents

Protecting Your Child from RSV ([English](#) | [French \(Français\)](#) | [Simplified Chinese \(简体中文\)](#) | [Traditional Chinese \(繁體中文\)](#) | [Arabic \(عربي\)](#) | [Italian \(Italiano\)](#) | [Punjabi \(ਪੰਜਾਬੀ\)](#) | [Spanish \(Español\)](#))

This fact sheet helps parents and expectant parents learn:

- what RSV is and why it can be serious for infants;
- available options to help protect their baby from RSV; and
- questions they may wish to discuss with their healthcare provider.

Providers are encouraged to share this resource with patients and families.

For Indigenous Families and Caregivers

Protecting Your Child from RSV ([English](#) | [French \(Français\)](#) | [Cree](#) | [Inuktitut](#) | [Ojibway](#) | [Mohawk](#))

Developed in partnership with the Indigenous Primary Health Care Council (IPHCC), this fact sheet provides culturally relevant information for Indigenous parents, families and caregivers in Ontario.

For Healthcare Providers

Protecting Infants and High-Risk Children During RSV ([English](#) | [French \(Français\)](#))

This resource summarizes Ontario's RSV prevention program, available prevention options, real-world effectiveness data, and key information to support discussions with families.

A [poster](#) for healthcare spaces with QR codes linking directly to the parent fact sheets in multiple languages is also available for download.





Number of Doses

Nirsevimab (Beyfortus®) dosing is dependent on the age and weight of the recipient:

- Infants born during the RSV season: A single dose is administered based on the infant's weight at the time of administration.
 - Infants < 5kg: 50 mg in 0.5 mL (100 mg/mL)
 - Infants ≥ 5kg: 100 mg in 1.0 mL (100 mg/mL)
- Infants born outside of the RSV season (includes those infants born from April 1 up to the start of their first RSV season (i.e., less than 8 months): A single dose is recommended based on the infant's weight at the time of administration.
 - Infants < 5 kg: 50 mg in 0.5 mL (100 mg/mL)
 - Infants ≥ 5 kg: 100 mg in 1.0 mL (100 mg/mL)

Administration should be targeted shortly before the start of the RSV season but can continue to be administered during the season.

- Infants and children who are at continued high-risk and between 8 and 24 months of age:

Administration of a one-time 200 mg dose given as two 1.0 mL intramuscular injections of 100 mg/mL of nirsevimab (Beyfortus®) administered in two separate injection sites should be targeted shortly before the start of their second RSV season (i.e., early October), but can be administered during the season if necessary. For children weighing less than 10 kg, a single dose of 100 mg may be considered based on clinical discretion.

Nirsevimab (Beyfortus®) Administration Guidelines for Infants and Children

Category	Weight	Dose	Timing
Infants born during the current RSV season [∞]	< 5 kg	50 mg in 0.5 mL (100 mg/mL)	Administered from birth
	≥ 5 kg	100 mg in 1 mL (100 mg/mL)	Administered from birth
Infants born April 1 or after and less than 8 months of age at the time of immunization	< 5 kg	50 mg in 0.5 mL (100 mg/mL)	Shortly before or during the RSV season [∞]
	≥ 5 kg	100 mg in 1 mL (100 mg/mL)	Shortly before or during the RSV season [∞]
Children over 8 months and less than 24 months of age and at continued high-risk from RSV infection	N/A	200 mg (two 1 mL injections of 100 mg/mL) [†]	Shortly before or during the RSV season [∞]
[∞] Due to the seasonality of the RSV virus, nirsevimab (Beyfortus®) should be administered shortly before and during the active RSV season. Nirsevimab (Beyfortus®) should be offered to eligible infants and children beginning October 1 each year, based on specific timing of product availability and throughout the RSV season.			
[†] If a child weighs less than 10 kg entering their second RSV season, consideration can be given to administering a single dose of 100 mg at the clinical discretion of the health care provider.			

(Ontario Ministry of Health, 2026).





Infant, high-risk and pregnancy immunization products

Vaccine	Infant or high-risk children (up to 24 months of age)	Pregnant women
Product monograph	Beyfortus®	Abrysvo®
Manufacturer	Sanofi	Pfizer
Protects against	RSV	RSV
Product type	monoclonal antibody (mAb)	Bivalent (RSV A and B) stabilized prefusion F protein subunit vaccine (RSVpreF)
Eligibility Criteria	- Infants born April 1 or after and less than 8 months of age at the time of immunization. - Children less than 24 months of age who remain vulnerable to severe RSV disease, following a discussion with a pediatric specialist.	Pregnant women 28-36 weeks gestation that will deliver during RSV season. Note: Administration before 32 weeks gestation is considered off-label and is solely subject to the clinical judgment of the health care provider.
Dosage	Based on weight 50 mg in 0.5 mL (100 mg/mL) 100 mg in 1.0 mL (100 mg/mL)	0.5 mL
Route of administration	Intramuscular injection (IM)	Intramuscular injection (IM)
Package format	Pre-filled syringe 1 unit per pack	One vial of powder with pre-filled syringe with diluent and vial adapter 1 unit per pack 10 units per pack
Package size (cm) L x W x H	14.4 x 5.1 x 2.4 (both 50 mg and 100mg doses)	1 pack: 10.7 x 3.7 x 7.4 10 pack: 20.7x 8 x 13.1
Reconstitution	N/A	Lyophilized vaccine must be reconstituted using vial adapter and only with diluent provided

(Ontario Ministry of Health, 2026).





Catch up/Immunization Clinics:

Infant RSV Immunization Clinics

Protect your little one from RSV this season

Clinics are offering Beyfortus (nirsevimab) to help prevent severe lung disease caused by Respiratory Syncytial Virus (RSV). Immunizations are available to all babies born on or after April 1, 2026. When booking your appointment, please confirm with the clinic that Beyfortus (nirsevimab) is available upon scheduling.



Orillia

1 Huronia NP-Led Clinic (Orillia)
250 West Street North, Unit 6, Orillia, ON L0L 1W0
Phone: 705-835-7545
Website: <https://www.huronianpic.ca/children-teens-clinic>

2 Huronia NP-Led Clinic (Oro-Medonte)
3331 Line 4 North, Oro Medonte, ON L0L 1W0
Phone: 705-835-7545
Website: <https://www.huronianpic.ca/children-teens-clinic>

Barrie and Area

3 Outpatient Child and Youth Clinic, Royal Victoria Hospital
201 Georgian Drive, Barrie, ON L4M 6M2
Phone: 705-728-9090 extension 47463
Note: Clinics run from October-November

4 Simcoe Muskoka District Health Unit Immunization Clinics
Website: <https://www.simcoemuskokahealth.org/Topics/Immunization/Clinics>
Note: Locations in Barrie, Collingwood, Cookstown, Gravenhurst, Huntsville, Midland & Orillia

5 Stevenson Memorial Hospital
Phone: 705-435-3377 ext. 2318
Email: MINT@smhosp.on.ca

Mississauga and Brampton

10 Mississauga Paediatric Care Clinic
89 Queensway West, Unit 604, Mississauga, ON L5B 2V2
Phone: 905-507-3019 or 905-238-0227
Notes: By appointment only. Book using <https://patient.medscohealth.com/booking/moht-pediatric-care-clinic>

11 Carepoint Health (West Mississauga)
2695 North Sheridan Way, Suite 120, Mississauga, ON L5K 2N6
Phone: 905-362-3508

12 CarePoint Health (East Mississauga)
90 Burnhamthorpe Road W., Sussex Building, Suite 210C, Mississauga, ON L5B 3C3
Phone: 905-362-3508

13 The Four Corners Clinic
7205 Goreway Drive, Mississauga, ON L4T 2T9
Phone: 905-677-9599

14 Bramelea Community Health Centre
40 Finchgate Blvd., Suite 224, Brampton, ON
Phone: 905-451-6959

Georgina

6 Georgina NP-Led Clinic
21071 Dalton Road, Box 340, Sutton, ON L0E 1R0
Phone: 905-722-3251
Website: <https://www.huronianpic.ca/children-teens-clinic>

York Region

7 Whitchurch-Stouffville Community Health Clinic
37 Sandford Drive, Suite 301, Stouffville, ON L4A 3Z2
Phone: 905-472-7658
Notes: Open Mon to Fri 8:30 AM - 4:30 PM. Please call to book RSV appointments.

8 Uxbridge Community Health Clinic
34 Campbell Drive, Building B, Uxbridge, ON L9P 1R5
(Inside Oak Tree Medical Building)
Phone: 905-472-7658

9 York Region Public Health
Website: <https://www.york.ca/newsroom/campaigns-projects/build-protection-every-layer>
Locations: Newmarket, Georgina, Unionville, Richmond Hill, Vaughan



Looking for a Primary Care Provider in Halton Region?

Halton Region Family Physicians

Immunizations available across select family physician clinics across Halton region. To see all locations and to book online, visit: <https://www.halton.ca/for-residents/public-health/halton-physicians-accepting-new-patients>

